{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:03:25Z","timestamp":1784610205186,"version":"3.55.0"},"reference-count":83,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie"},{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012317","name":"Astellas Pharma Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012317","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008021","name":"BMS Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jazz Pharma Canada"},{"DOI":"10.13039\/100009009","name":"Novartis Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009009","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100023798","name":"Servier Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023798","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taiho Canada"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>These are the third Canadian consensus guidelines on the management of acute myeloid leukemia (AML) in older patients. The first was published in 2013, and the second in 2017. The management of AML in older patients changed significantly over this time span, with decreasing emphasis on the use of intensive chemotherapy and the adoption of new standards of care based on less-intensive therapies: first azacitidine + venetoclax combinations, followed by azacitidine + ivosidenib. Increased use of these new therapies in older patients has raised questions about their use, including how to determine patient suitability, select the most effective therapy, and manage dosing and toxicity. In this third Canadian guideline, we address these questions to provide clarity around these new standards of care and improve clinician understanding and confidence in using them. As more new targeted agents become available and hypomethylating agent-based triplet combinations are used more widely, we fully anticipate that we will, in some years\u2019 time, write a fourth guideline on the management of AML in older patients.<\/jats:p>","DOI":"10.3390\/curroncol33070429","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:09:09Z","timestamp":1784527749000},"page":"429","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus"],"prefix":"10.3390","volume":"33","author":[{"given":"Andre C.","family":"Schuh","sequence":"first","affiliation":[{"name":"Departments of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Chornenki","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada"},{"name":"Institute of Health Policy, Management and Evaluation Toronto, University of Toronto, ON M5T 3M6, Canada"},{"name":"Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7622-4065","authenticated-orcid":false,"given":"Mohamed A.","family":"Elemary","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Centre, Saskatoon, SK S7N 4H4, Canada"},{"name":"Division of Oncology, College of Medicine, University of Saskatchewan, Hematology, Saskatoon, SK S7N 5E5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elsawy","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Oncology, Department of Medicine, Dalhousie University, Halifax, NS B3H 2Y9, Canada"},{"name":"QEII Health Sciences Centre, Halifax, NS B3H 3A7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8776-4083","authenticated-orcid":false,"given":"Brett L.","family":"Houston","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 3P5, Canada"},{"name":"Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-1480","authenticated-orcid":false,"given":"Brian","family":"Leber","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Mozessohn","sequence":"additional","affiliation":[{"name":"Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0122-6138","authenticated-orcid":false,"given":"Mitchell","family":"Sabloff","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"},{"name":"The Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Salter","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sanford","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9095-8789","authenticated-orcid":false,"given":"Joseph","family":"Brandwein","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"ref_1","first-page":"141","article-title":"Treatment of older patients with acute myeloid leukemia (AML): A Canadian consensus","volume":"3","author":"Brandwein","year":"2013","journal-title":"Am. J. Blood Res."},{"key":"ref_2","first-page":"30","article-title":"Treatment of older patients with acute myeloid leukemia (AML): Revised Canadian consensus guidelines","volume":"7","author":"Brandwein","year":"2017","journal-title":"Am. J. Blood Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"Schuh, A.C. (2019, January 19). The Canadian AML Treatment Landscape\u20142019. Proceedings of the Canadian Conference on Myelodysplastic Syndromes 2019, Vancouver, BC, Canada."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10410","DOI":"10.3390\/curroncol30120759","article-title":"The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus","volume":"30","author":"Bergeron","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2024013744","article-title":"Fitness assessment in acute myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"9","author":"Venditti","year":"2025","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1038\/s41375-025-02644-0","article-title":"Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)","volume":"39","author":"Cusan","year":"2025","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"CMAJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102254","DOI":"10.1016\/j.jgo.2025.102254","article-title":"Geriatric assessment in older adults with acute myeloid leukemia: A Young International Society of Geriatric Oncology narrative review","volume":"16","author":"Ciccone","year":"2025","journal-title":"J. Geriatr. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update","volume":"41","author":"Dale","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26079","article-title":"Determination of fitness and therapeutic options in older patients with acute myeloid leukemia","volume":"96","author":"Cortes","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000535500","article-title":"Geriatric Assessment in Acute Myeloid Leukemia","volume":"147","author":"Woods","year":"2024","journal-title":"Acta Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ferrara, F., Geissler, K., Mehta, P., Montesinos, P., and Venditti, A. (2025). Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: Perspectives from a European expert panel. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1642472"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11864-025-01341-5","article-title":"Care of Older Adults with Acute Myeloid Leukemia: The Role of Geriatric Assessment","volume":"26","author":"Kc","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101288","DOI":"10.1016\/j.blre.2025.101288","article-title":"Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy","volume":"73","author":"Palmieri","year":"2025","journal-title":"Blood Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2025016114","article-title":"Finding the right fit: Assessment of fitness in AML","volume":"9","author":"Chornenki","year":"2025","journal-title":"Blood Adv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1182\/bloodadvances.2025016235","article-title":"Moving beyond the eyeball test for fitness assessment in AML","volume":"9","author":"Yates","year":"2025","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2025-6","article-title":"Results from PARADIGM\u2014A phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia","volume":"146","author":"Fathi","year":"2025","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-025-01346-1","article-title":"Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms","volume":"15","author":"Gangat","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-naive TP53-mutated acute myeloid leukemia: A systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/ajh.27694","article-title":"A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults with AML","volume":"100","author":"Bhatt","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.24.00259","article-title":"Treatment Intensification with Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients with AML: Results from the NCRI AML18 Trial","volume":"43","author":"Russell","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.2024026700","article-title":"Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: Results of a phase 1b study","volume":"145","author":"Mantzaris","year":"2025","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2023020630","article-title":"Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: The UK NCRI AML18 trial","volume":"142","author":"Freeman","year":"2023","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: A phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3324\/haematol.2009.011809","article-title":"A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia","volume":"95","author":"Terwey","year":"2010","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymthe.2005.09.011","article-title":"Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders","volume":"13","author":"Baron","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/1055-9965.EPI-19-1277","article-title":"Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful Benefits","volume":"29","author":"Richardson","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Min, G.J., Cho, B.S., Kwag, D., Park, S.S., Park, S., Yoon, J.H., Lee, S.E., Eom, K.S., Kim, Y.J., and Lee, S. (2023). Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1281782"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/bloodadvances.2025016260","article-title":"Pilot study of an inpatient physical activity intervention for older adults treated intensively for acute myeloid leukemia","volume":"9","author":"Klepin","year":"2025","journal-title":"Blood Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1182\/bloodadvances.2019000790","article-title":"Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults","volume":"3","author":"Derman","year":"2019","journal-title":"Blood Adv."},{"key":"ref_36","unstructured":"Surveillance, Epidemiology, and End Results Program (2020). Cancer Stat Facts: Leukemia\u2014Acute Myeloid Leukemia (AML), National Cancer Institute, DCCPS, Surveillance Research Program."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.2022015832","article-title":"Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ejh.14278","article-title":"Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy","volume":"113","author":"Acker","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/j.clml.2025.01.024","article-title":"A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia with Azacitidine Plus Venetoclax","volume":"25","author":"Brandwein","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-021-00555-8","article-title":"6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy","volume":"11","author":"Wei","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2022016963","article-title":"Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"Pratz","year":"2024","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: The 2024 ELN recommendations","volume":"144","author":"DiNardo","year":"2024","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in Patients with Poor-risk Cytogenetics with or Without TP53 Mutations Treated with Venetoclax and Azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood-2021-153960","article-title":"Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML","volume":"138","author":"Venugopal","year":"2021","journal-title":"Blood"},{"key":"ref_51","unstructured":"Roboz, G.J., Zeidan, A.M., Mannis, G., Montesinos, P., Sangerman, M.A., Savona, M., Odenike, O., McCloskey, J., Amin, H., and Fathi, A. (2025). All-oral decitabine-cedazuridine + venetoclax in patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy: Phase 1\/2 clinical trial results. EHA, 4159212. Available online: https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4159212\/gail.roboz.all-oral.decitabine-cedazuridine.28dec-c29.2B.venetoclax.28ven29.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Asearch%3Dviale."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1182\/bloodadvances.2025016399","article-title":"Long-term results from the AGILE study of azacitidine plus ivosidenib vs. placebo in newly diagnosed IDH1-mutated AML","volume":"9","author":"Montesinos","year":"2025","journal-title":"Blood Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","article-title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: Long-term analysis of a phase II randomized trial","volume":"100","author":"Heuser","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1002\/ajh.26012","article-title":"An evaluation of no-treatment decisions in patients with newly diagnosed acute myeloid leukemia","volume":"96","author":"Brandwein","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"150959","DOI":"10.1016\/j.soncn.2019.150959","article-title":"Integration of Palliative Care into Acute Myeloid Leukemia Care","volume":"35","author":"Webb","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamaoncol.2020.6343","article-title":"Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia: A Randomized Clinical Trial","volume":"7","author":"LeBlanc","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1182\/blood-2024-207045","article-title":"Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia","volume":"144","author":"Iat","year":"2024","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"100152","DOI":"10.1016\/j.bneo.2025.100152","article-title":"Ivosidenib or venetoclax combined with hypomethylating agents in IDH1-mutated acute myeloid leukemia: A real-world study","volume":"2","author":"Lachowiez","year":"2025","journal-title":"Blood Neoplasia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Urbino, I., Secreto, C., Olivi, M., Apolito, V., D\u2019Ardia, S., Frairia, C., Giai, V., Aydin, S., Freilone, R., and Dellacasa, C. (2021). Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021. Cancers, 13.","DOI":"10.3390\/cancers13205075"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2040620719882822","DOI":"10.1177\/2040620719882822","article-title":"Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy","volume":"10","author":"DiNardo","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Saiyin, T., Christou, G., Sabloff, M., Crosbie, T., Nguyen-Tham, K.M., and Fulcher, J. (2025). Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32040213"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/ajh.27180","article-title":"Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival","volume":"99","author":"Karrar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-025-01324-7","article-title":"Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: Real-world experience from the Hokkaido Leukemia Net","volume":"15","author":"Kanaya","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.27515","article-title":"The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia","volume":"100","author":"DiNardo","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/ajh.27417","article-title":"Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment","volume":"99","author":"Garciaz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"390.e1","DOI":"10.1016\/j.jtct.2023.03.008","article-title":"TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia","volume":"29","author":"Mason","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1080\/10428194.2020.1817445","article-title":"Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: Expert panel review","volume":"61","author":"Cortes","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-023-02001-z","article-title":"Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: Results from the randomized, phase 3 BRIGHT AML 1019 trial","volume":"37","author":"Sekeres","year":"2023","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2026","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","article-title":"Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia","volume":"5","author":"Maiti","year":"2021","journal-title":"Blood Adv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia with Venetoclax and Azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/ajh.27087","article-title":"Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel","volume":"98","author":"Ravandi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1182\/blood-2024-201875","article-title":"Efficacy and Safety of Revumenib in the Treatment of Acute Myeloid Leukemia with KMT2A Rearrangements or NPM1 Mutations: A Systematic Review","volume":"144","author":"Jamil","year":"2024","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Piccini, M., Mannelli, F., and Coltro, G. (2023). The Role of Venetoclax in Relapsed\/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions. Bioengineering, 10.","DOI":"10.3390\/bioengineering10050591"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/429\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:18:45Z","timestamp":1784607525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":83,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["curroncol33070429"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33070429","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]}}}